TY  - JOUR
AU  - Predarska, Ivana
AU  - Saoud, Mohamad
AU  - Drača, Dijana
AU  - Morgan, Ibrahim
AU  - Komazec, Teodora
AU  - Eichhorn, Thomas
AU  - Mihajlović, Ekatarina
AU  - Dunđerović, Duško
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
AU  - Kaluđerović, Goran N.
PY  - 2022
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5238
AB  - The main reasons for the limited clinical efficacy of the platinum(II)-based agent cisplatin
include drug resistance and significant side effects. Due to their better stability, as well as the
possibility to introduce biologically active ligands in their axial positions constructing multifunctional
prodrugs, creating platinum(IV) complexes is a tempting strategy for addressing these limitations.
Another strategy for developing chemotherapeutics with lower toxicity relies on the ability of
nanoparticles to accumulate in greater quantities in tumor tissues through passive targeting. To
combine the two approaches, three platinum(IV) conjugates based on a cisplatin scaffold containing
in the axial positions derivatives of caffeic and ferulic acid were prepared and loaded into SBA-
15 to produce the corresponding mesoporous silica nanoparticles (MSNs). The free platinum(IV)
conjugates demonstrated higher or comparable activity with respect to cisplatin against different
human breast cancer cell lines, while upon immobilization, superior antiproliferative activity with
markedly increased cytotoxicity (more than 1000-fold lower IC50 values) compared to cisplatin was
observed. Mechanistic investigations with the most potent conjugate, cisplatin-diacetyl caffeate (1),
and the corresponding MSNs (SBA-15|1) in a 4T1 mouse breast cancer cell line showed that these
compounds induce apoptotic cell death causing strong caspase activation. In vivo, in BALB/c mice,
1 and SBA-15|1 inhibited the tumor growth while decreasing the necrotic area and lowering the
mitotic rate.
PB  - Basel: MDPI
T2  - Nanomaterials
T1  - Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines
IS  - 21
VL  - 12
DO  - 10.3390/nano12213767
SP  - 3767
ER  - 

@article{
author = "Predarska, Ivana and Saoud, Mohamad and Drača, Dijana and Morgan, Ibrahim and Komazec, Teodora and Eichhorn, Thomas and Mihajlović, Ekatarina and Dunđerović, Duško and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie and Kaluđerović, Goran N.",
year = "2022",
abstract = "The main reasons for the limited clinical efficacy of the platinum(II)-based agent cisplatin
include drug resistance and significant side effects. Due to their better stability, as well as the
possibility to introduce biologically active ligands in their axial positions constructing multifunctional
prodrugs, creating platinum(IV) complexes is a tempting strategy for addressing these limitations.
Another strategy for developing chemotherapeutics with lower toxicity relies on the ability of
nanoparticles to accumulate in greater quantities in tumor tissues through passive targeting. To
combine the two approaches, three platinum(IV) conjugates based on a cisplatin scaffold containing
in the axial positions derivatives of caffeic and ferulic acid were prepared and loaded into SBA-
15 to produce the corresponding mesoporous silica nanoparticles (MSNs). The free platinum(IV)
conjugates demonstrated higher or comparable activity with respect to cisplatin against different
human breast cancer cell lines, while upon immobilization, superior antiproliferative activity with
markedly increased cytotoxicity (more than 1000-fold lower IC50 values) compared to cisplatin was
observed. Mechanistic investigations with the most potent conjugate, cisplatin-diacetyl caffeate (1),
and the corresponding MSNs (SBA-15|1) in a 4T1 mouse breast cancer cell line showed that these
compounds induce apoptotic cell death causing strong caspase activation. In vivo, in BALB/c mice,
1 and SBA-15|1 inhibited the tumor growth while decreasing the necrotic area and lowering the
mitotic rate.",
publisher = "Basel: MDPI",
journal = "Nanomaterials",
title = "Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines",
number = "21",
volume = "12",
doi = "10.3390/nano12213767",
pages = "3767"
}

Predarska, I., Saoud, M., Drača, D., Morgan, I., Komazec, T., Eichhorn, T., Mihajlović, E., Dunđerović, D., Mijatović, S., Maksimović-Ivanić, D., Hey-Hawkins, E.,& Kaluđerović, G. N.. (2022). Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines. in Nanomaterials
Basel: MDPI., 12(21), 3767.
https://doi.org/10.3390/nano12213767

Predarska I, Saoud M, Drača D, Morgan I, Komazec T, Eichhorn T, Mihajlović E, Dunđerović D, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E, Kaluđerović GN. Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines. in Nanomaterials. 2022;12(21):3767.
doi:10.3390/nano12213767 .

Predarska, Ivana, Saoud, Mohamad, Drača, Dijana, Morgan, Ibrahim, Komazec, Teodora, Eichhorn, Thomas, Mihajlović, Ekatarina, Dunđerović, Duško, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, Kaluđerović, Goran N., "Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines" in Nanomaterials, 12, no. 21 (2022):3767,
https://doi.org/10.3390/nano12213767 . .

TY  - JOUR
AU  - Krajnović, Tamara
AU  - Pantelić, Nebojša Đ.
AU  - Wolf, Katharina
AU  - Eichhorn, Thomas
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Wessjohann, Ludger A.
AU  - Kaluđerović, Goran N.
PY  - 2022
UR  - https://www.mdpi.com/1996-1944/15/14/5028
UR  - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9320346
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5089
AB  - Xanthohumol (XN) and isoxanthohumol (IXN), prenylated flavonoids from Humulus lupulus, have been shown to possess antitumor/cancerprotective, antioxidant, antiinflammatory, and antiangiogenic properties. In this study, mesoporous silica (SBA-15) was loaded with different amounts of xanthohumol and isoxanthohumol and characterized by standard analytical methods. The anticancer potential of XN and IXN loaded into SBA-15 has been evaluated against malignant mouse melanoma B16F10 cells. When these cells were treated with SBA-15 containing xanthohumol, an increase of the activity correlated with a higher immobilization rate of XN was observed. Considering the amount of XN loaded into SBA-15 (calculated from TGA), an improved antitumor potential of XN was observed (IC50 = 10.8 ± 0.4 and 11.8 ± 0.5 µM for SBA-15|XN2 and SBA-15|XN3, respectively; vs. IC50 = 18.5 ± 1.5 µM for free XN). The main mechanism against tumor cells of immobilized XN includes inhibition of proliferation and autophagic cell death. The MC50 values for SBA-15 loaded with isoxanthohumol were over 300 µg/mL in all cases investigated.
PB  - Basel: MDPI
T2  - Materials (Basel, Switzerland)
T1  - Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.
IS  - 14
VL  - 15
DO  - 10.3390/ma15145028
SP  - 5028
ER  - 

@article{
author = "Krajnović, Tamara and Pantelić, Nebojša Đ. and Wolf, Katharina and Eichhorn, Thomas and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Wessjohann, Ludger A. and Kaluđerović, Goran N.",
year = "2022",
abstract = "Xanthohumol (XN) and isoxanthohumol (IXN), prenylated flavonoids from Humulus lupulus, have been shown to possess antitumor/cancerprotective, antioxidant, antiinflammatory, and antiangiogenic properties. In this study, mesoporous silica (SBA-15) was loaded with different amounts of xanthohumol and isoxanthohumol and characterized by standard analytical methods. The anticancer potential of XN and IXN loaded into SBA-15 has been evaluated against malignant mouse melanoma B16F10 cells. When these cells were treated with SBA-15 containing xanthohumol, an increase of the activity correlated with a higher immobilization rate of XN was observed. Considering the amount of XN loaded into SBA-15 (calculated from TGA), an improved antitumor potential of XN was observed (IC50 = 10.8 ± 0.4 and 11.8 ± 0.5 µM for SBA-15|XN2 and SBA-15|XN3, respectively; vs. IC50 = 18.5 ± 1.5 µM for free XN). The main mechanism against tumor cells of immobilized XN includes inhibition of proliferation and autophagic cell death. The MC50 values for SBA-15 loaded with isoxanthohumol were over 300 µg/mL in all cases investigated.",
publisher = "Basel: MDPI",
journal = "Materials (Basel, Switzerland)",
title = "Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.",
number = "14",
volume = "15",
doi = "10.3390/ma15145028",
pages = "5028"
}

Krajnović, T., Pantelić, N. Đ., Wolf, K., Eichhorn, T., Maksimović-Ivanić, D., Mijatović, S., Wessjohann, L. A.,& Kaluđerović, G. N.. (2022). Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.. in Materials (Basel, Switzerland)
Basel: MDPI., 15(14), 5028.
https://doi.org/10.3390/ma15145028

Krajnović T, Pantelić NĐ, Wolf K, Eichhorn T, Maksimović-Ivanić D, Mijatović S, Wessjohann LA, Kaluđerović GN. Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.. in Materials (Basel, Switzerland). 2022;15(14):5028.
doi:10.3390/ma15145028 .

Krajnović, Tamara, Pantelić, Nebojša Đ., Wolf, Katharina, Eichhorn, Thomas, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Wessjohann, Ludger A., Kaluđerović, Goran N., "Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells." in Materials (Basel, Switzerland), 15, no. 14 (2022):5028,
https://doi.org/10.3390/ma15145028 . .

TY  - JOUR
AU  - Arlt, Sören
AU  - Petković, Vladana
AU  - Ludwig, Gerd
AU  - Eichhorn, Thomas
AU  - Lang, Heinrich
AU  - Rüffer, Tobias
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Kaluđerović, Goran
PY  - 2021
UR  - https://www.mdpi.com/1420-3049/26/7/1860
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4220
AB  - Neutral [Ru(η6-arene)Cl2{Ph2P(CH2)3SPh-κP}] (arene = benzene, indane, 1,2,3,4-tetrahydronaphthalene: 2a, 2c and 2d) and cationic [Ru(η6-arene)Cl(Ph2P(CH2)3SPh-κP,κS)]X complexes (arene = mesitylene, 1,4-dihydronaphthalene; X = Cl: 3b, 3e; arene = benzene, mesitylene, indane, 1,2,3,4-tetrahydronaphthalene, and 1,4-dihydronaphthalene; X = PF6: 4a–4e) complexes were prepared and characterized by elemental analysis, IR, 1H, 13C and 31P NMR spectroscopy and also by single-crystal X-ray diffraction analyses. The stability of the complexes has been investigated in DMSO. Complexes have been assessed for their cytotoxic activity against 518A2, 8505C, A253, MCF-7 and SW480 cell lines. Generally, complexes exhibited activity in the lower micromolar range; moreover, they are found to be more active than cisplatin. For the most active ruthenium(II) complex, 4b, bearing mesitylene as ligand, the mechanism of action against 8505C cisplatin resistant cell line was determined. Complex 4b induced apoptosis accompanied by caspase activation.
PB  - MDPI
T2  - Molecules
T1  - Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand
IS  - 7
VL  - 26
DO  - 10.3390/molecules26071860
SP  - 1860
ER  - 

@article{
author = "Arlt, Sören and Petković, Vladana and Ludwig, Gerd and Eichhorn, Thomas and Lang, Heinrich and Rüffer, Tobias and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Kaluđerović, Goran",
year = "2021",
abstract = "Neutral [Ru(η6-arene)Cl2{Ph2P(CH2)3SPh-κP}] (arene = benzene, indane, 1,2,3,4-tetrahydronaphthalene: 2a, 2c and 2d) and cationic [Ru(η6-arene)Cl(Ph2P(CH2)3SPh-κP,κS)]X complexes (arene = mesitylene, 1,4-dihydronaphthalene; X = Cl: 3b, 3e; arene = benzene, mesitylene, indane, 1,2,3,4-tetrahydronaphthalene, and 1,4-dihydronaphthalene; X = PF6: 4a–4e) complexes were prepared and characterized by elemental analysis, IR, 1H, 13C and 31P NMR spectroscopy and also by single-crystal X-ray diffraction analyses. The stability of the complexes has been investigated in DMSO. Complexes have been assessed for their cytotoxic activity against 518A2, 8505C, A253, MCF-7 and SW480 cell lines. Generally, complexes exhibited activity in the lower micromolar range; moreover, they are found to be more active than cisplatin. For the most active ruthenium(II) complex, 4b, bearing mesitylene as ligand, the mechanism of action against 8505C cisplatin resistant cell line was determined. Complex 4b induced apoptosis accompanied by caspase activation.",
publisher = "MDPI",
journal = "Molecules",
title = "Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand",
number = "7",
volume = "26",
doi = "10.3390/molecules26071860",
pages = "1860"
}

Arlt, S., Petković, V., Ludwig, G., Eichhorn, T., Lang, H., Rüffer, T., Mijatović, S., Maksimović-Ivanić, D.,& Kaluđerović, G.. (2021). Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand. in Molecules
MDPI., 26(7), 1860.
https://doi.org/10.3390/molecules26071860

Arlt S, Petković V, Ludwig G, Eichhorn T, Lang H, Rüffer T, Mijatović S, Maksimović-Ivanić D, Kaluđerović G. Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand. in Molecules. 2021;26(7):1860.
doi:10.3390/molecules26071860 .

Arlt, Sören, Petković, Vladana, Ludwig, Gerd, Eichhorn, Thomas, Lang, Heinrich, Rüffer, Tobias, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Kaluđerović, Goran, "Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand" in Molecules, 26, no. 7 (2021):1860,
https://doi.org/10.3390/molecules26071860 . .

TY  - JOUR
AU  - Momčilović, Miljana
AU  - Eichhorn, Thomas
AU  - Blaževski, Jana
AU  - Schmidt, Harry
AU  - Kaluđerović, Goran N.
AU  - Stošić-Grujičić, Stanislava
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/1979
AB  - T cell differentiation into distinct T helper (Th) subpopulations is
   crucial in governing acquired immune responses as well as some
   inflammatory and autoimmune disorders. This study investigated potential
   of the novel neutral binuclear ruthenium(II) complexes 1-8 with general
   formula {[}\{RuCl2(eta(6)-p-cym)\}(2)mu-((NN)-N-a (c))] ((NN)-N-a (c) =
   bis(nicotinate)- and bis(iso-nicotinate)-polyethylene glycol esters;
   (3-py)COO(CH2CH2O) (n) CO(3-py) and (4-py)COO(CH2CH2O) (n) CO(4-py); n =
   1-4), as well as {[}RuCl2(eta(6)-p-cym)(nic)] (R1, nic = nicotinate) and
   {[}RuCl2(eta(6)-p-cym)(inic)] (R2, inic = isonicotinate) as an
   immunomodulatory agents capable to direct Th cell differentiation. From
   all investigated complexes,
   {[}\{RuCl2(eta(6)-p-cym)\}(2)mu-\{(3-py)COO(CH2CH2O)(4)CO(3-py)\}] (4)
   was selected for further study because it did not affect splenocyte
   viability (in concentration up to 50 mu M), but significantly reduced
   secretion of representative Th1 cytokine, IFN-gamma induced by T cell
   mitogen. Besides IFN-gamma, 4 inhibited dose dependently expression and
   production of representative Th17 cytokine, IL-17, in these cells.
   Otherwise, the production of anti-inflammatory cytokines IL-4 and IL-10
   was upregulated. Also, 4 significantly increased CD4(+)CD25(+)FoxP3(+)
   Treg cell frequency in the activated splenocytes. Moreover, ConA-induced
   expression of Th1 transcription factors, T-bet and STAT1, as well as of
   Th17-related protein STAT3 was attenuated upon exposure to 4, while the
   expression of Th2-related transcription factor GATA3 remained stable. In
   conclusion, ruthenium(II) complex 4 modulates immune system cell
   functions in vitro by inhibiting T cell differentiation towards
   pathogenic Th1/Th17 phenotype and inducing a regulatory phenotype
   characterized by IL-10 and IL-4 production, which may provide novel
   therapeutic opportunities for immune-inflammatory and/or autoimmune
   disorders.
T2  - Journal of Biological Inorganic Chemistry
T1  - In vitro effects of binuclear (eta (6)-p-cymene)ruthenium(II) complex
 containing bridging bis(nicotinate)-polyethylene glycol ester ligand on
 differentiation pathways of murine Th lymphocytes activated by T cell
 mitogen
IS  - 3
VL  - 20
DO  - 10.1007/s00775-015-1242-x
SP  - 575
EP  - 583
ER  - 

@article{
author = "Momčilović, Miljana and Eichhorn, Thomas and Blaževski, Jana and Schmidt, Harry and Kaluđerović, Goran N. and Stošić-Grujičić, Stanislava",
year = "2015",
abstract = "T cell differentiation into distinct T helper (Th) subpopulations is
   crucial in governing acquired immune responses as well as some
   inflammatory and autoimmune disorders. This study investigated potential
   of the novel neutral binuclear ruthenium(II) complexes 1-8 with general
   formula {[}\{RuCl2(eta(6)-p-cym)\}(2)mu-((NN)-N-a (c))] ((NN)-N-a (c) =
   bis(nicotinate)- and bis(iso-nicotinate)-polyethylene glycol esters;
   (3-py)COO(CH2CH2O) (n) CO(3-py) and (4-py)COO(CH2CH2O) (n) CO(4-py); n =
   1-4), as well as {[}RuCl2(eta(6)-p-cym)(nic)] (R1, nic = nicotinate) and
   {[}RuCl2(eta(6)-p-cym)(inic)] (R2, inic = isonicotinate) as an
   immunomodulatory agents capable to direct Th cell differentiation. From
   all investigated complexes,
   {[}\{RuCl2(eta(6)-p-cym)\}(2)mu-\{(3-py)COO(CH2CH2O)(4)CO(3-py)\}] (4)
   was selected for further study because it did not affect splenocyte
   viability (in concentration up to 50 mu M), but significantly reduced
   secretion of representative Th1 cytokine, IFN-gamma induced by T cell
   mitogen. Besides IFN-gamma, 4 inhibited dose dependently expression and
   production of representative Th17 cytokine, IL-17, in these cells.
   Otherwise, the production of anti-inflammatory cytokines IL-4 and IL-10
   was upregulated. Also, 4 significantly increased CD4(+)CD25(+)FoxP3(+)
   Treg cell frequency in the activated splenocytes. Moreover, ConA-induced
   expression of Th1 transcription factors, T-bet and STAT1, as well as of
   Th17-related protein STAT3 was attenuated upon exposure to 4, while the
   expression of Th2-related transcription factor GATA3 remained stable. In
   conclusion, ruthenium(II) complex 4 modulates immune system cell
   functions in vitro by inhibiting T cell differentiation towards
   pathogenic Th1/Th17 phenotype and inducing a regulatory phenotype
   characterized by IL-10 and IL-4 production, which may provide novel
   therapeutic opportunities for immune-inflammatory and/or autoimmune
   disorders.",
journal = "Journal of Biological Inorganic Chemistry",
title = "In vitro effects of binuclear (eta (6)-p-cymene)ruthenium(II) complex
 containing bridging bis(nicotinate)-polyethylene glycol ester ligand on
 differentiation pathways of murine Th lymphocytes activated by T cell
 mitogen",
number = "3",
volume = "20",
doi = "10.1007/s00775-015-1242-x",
pages = "575-583"
}

Momčilović, M., Eichhorn, T., Blaževski, J., Schmidt, H., Kaluđerović, G. N.,& Stošić-Grujičić, S.. (2015). In vitro effects of binuclear (eta (6)-p-cymene)ruthenium(II) complex
 containing bridging bis(nicotinate)-polyethylene glycol ester ligand on
 differentiation pathways of murine Th lymphocytes activated by T cell
 mitogen. in Journal of Biological Inorganic Chemistry, 20(3), 575-583.
https://doi.org/10.1007/s00775-015-1242-x

Momčilović M, Eichhorn T, Blaževski J, Schmidt H, Kaluđerović GN, Stošić-Grujičić S. In vitro effects of binuclear (eta (6)-p-cymene)ruthenium(II) complex
 containing bridging bis(nicotinate)-polyethylene glycol ester ligand on
 differentiation pathways of murine Th lymphocytes activated by T cell
 mitogen. in Journal of Biological Inorganic Chemistry. 2015;20(3):575-583.
doi:10.1007/s00775-015-1242-x .

Momčilović, Miljana, Eichhorn, Thomas, Blaževski, Jana, Schmidt, Harry, Kaluđerović, Goran N., Stošić-Grujičić, Stanislava, "In vitro effects of binuclear (eta (6)-p-cymene)ruthenium(II) complex
 containing bridging bis(nicotinate)-polyethylene glycol ester ligand on
 differentiation pathways of murine Th lymphocytes activated by T cell
 mitogen" in Journal of Biological Inorganic Chemistry, 20, no. 3 (2015):575-583,
https://doi.org/10.1007/s00775-015-1242-x . .

TY  - JOUR
AU  - Eichhorn, Thomas
AU  - Hey-Hawkins, Evamarie
AU  - Maksimović-Ivanić, Danijela
AU  - Mojić, Marija
AU  - Schmidt, Juergen
AU  - Mijatović, Sanja
AU  - Schmidt, Harry
AU  - Kaluđerović, Goran N.
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2099
AB  - Neutral binuclear ruthenium complexes 1, 2, 3, 4, 5, 6, 7, 8 of the
   general formula {[}\{RuCl2((6)-p-cym)\}(2)-(NN)] (NN=bis(nicotinate)-
   and bis(isonicotinate)-polyethylene glycol esters:
   (3-py)COO(CH2CH2O)(n)CO(3-py) and (4-py)COO(CH2CH2O)(n)CO(4-py), n
   =1-4), as well as mononuclear
   {[}RuCl2((6)-p-cym)((3-py)COO(CH2CH2OCH3)-N)], complex 9, were
   synthesized and characterized using elemental analysis and electrospray
   ionization high-resolution mass spectrometry, infrared, H-1 NMR and C-13
   NMR spectroscopies. Stability of the binuclear complexes in the presence
   of dimethylsulfoxide was studied. Furthermore, formation of a cationic
   complex containing bridging pyridine-based bidentate ligand was
   monitored using H-1 NMR spectroscopy. Ligand precursors, polyethylene
   glycol esters of nicotinic (L12HCl-L42HCl and L9HCl) and isonicotinic
   acid dihydrochlorides (L52HCl-L82HCl), binuclear ruthenium(II) complexes
   1, 2, 3, 4, 5, 6, 7, 8 and mononuclear complex 9 were tested for in
   vitro cytotoxicity against 518A2 (melanoma), 8505C (anaplastic thyroid
   cancer), A253 (head and neck tumour), MCF-7 (breast tumour) and SW480
   (colon carcinoma) cell lines. Copyright (c) 2014 John Wiley \& Sons,
   Ltd.
T2  - Applied Organometallic Chemistry
T1  - Binuclear dichlorido(eta(6)-p-cymene)ruthenium(II) complexes with
 bis(nicotinate)- and bis (isonicotinate)-polyethylene glycol ester
 ligands
IS  - 1
VL  - 29
DO  - 10.1002/aoc.3238
SP  - 20
EP  - 25
ER  - 

@article{
author = "Eichhorn, Thomas and Hey-Hawkins, Evamarie and Maksimović-Ivanić, Danijela and Mojić, Marija and Schmidt, Juergen and Mijatović, Sanja and Schmidt, Harry and Kaluđerović, Goran N.",
year = "2015",
abstract = "Neutral binuclear ruthenium complexes 1, 2, 3, 4, 5, 6, 7, 8 of the
   general formula {[}\{RuCl2((6)-p-cym)\}(2)-(NN)] (NN=bis(nicotinate)-
   and bis(isonicotinate)-polyethylene glycol esters:
   (3-py)COO(CH2CH2O)(n)CO(3-py) and (4-py)COO(CH2CH2O)(n)CO(4-py), n
   =1-4), as well as mononuclear
   {[}RuCl2((6)-p-cym)((3-py)COO(CH2CH2OCH3)-N)], complex 9, were
   synthesized and characterized using elemental analysis and electrospray
   ionization high-resolution mass spectrometry, infrared, H-1 NMR and C-13
   NMR spectroscopies. Stability of the binuclear complexes in the presence
   of dimethylsulfoxide was studied. Furthermore, formation of a cationic
   complex containing bridging pyridine-based bidentate ligand was
   monitored using H-1 NMR spectroscopy. Ligand precursors, polyethylene
   glycol esters of nicotinic (L12HCl-L42HCl and L9HCl) and isonicotinic
   acid dihydrochlorides (L52HCl-L82HCl), binuclear ruthenium(II) complexes
   1, 2, 3, 4, 5, 6, 7, 8 and mononuclear complex 9 were tested for in
   vitro cytotoxicity against 518A2 (melanoma), 8505C (anaplastic thyroid
   cancer), A253 (head and neck tumour), MCF-7 (breast tumour) and SW480
   (colon carcinoma) cell lines. Copyright (c) 2014 John Wiley \& Sons,
   Ltd.",
journal = "Applied Organometallic Chemistry",
title = "Binuclear dichlorido(eta(6)-p-cymene)ruthenium(II) complexes with
 bis(nicotinate)- and bis (isonicotinate)-polyethylene glycol ester
 ligands",
number = "1",
volume = "29",
doi = "10.1002/aoc.3238",
pages = "20-25"
}

Eichhorn, T., Hey-Hawkins, E., Maksimović-Ivanić, D., Mojić, M., Schmidt, J., Mijatović, S., Schmidt, H.,& Kaluđerović, G. N.. (2015). Binuclear dichlorido(eta(6)-p-cymene)ruthenium(II) complexes with
 bis(nicotinate)- and bis (isonicotinate)-polyethylene glycol ester
 ligands. in Applied Organometallic Chemistry, 29(1), 20-25.
https://doi.org/10.1002/aoc.3238

Eichhorn T, Hey-Hawkins E, Maksimović-Ivanić D, Mojić M, Schmidt J, Mijatović S, Schmidt H, Kaluđerović GN. Binuclear dichlorido(eta(6)-p-cymene)ruthenium(II) complexes with
 bis(nicotinate)- and bis (isonicotinate)-polyethylene glycol ester
 ligands. in Applied Organometallic Chemistry. 2015;29(1):20-25.
doi:10.1002/aoc.3238 .

Eichhorn, Thomas, Hey-Hawkins, Evamarie, Maksimović-Ivanić, Danijela, Mojić, Marija, Schmidt, Juergen, Mijatović, Sanja, Schmidt, Harry, Kaluđerović, Goran N., "Binuclear dichlorido(eta(6)-p-cymene)ruthenium(II) complexes with
 bis(nicotinate)- and bis (isonicotinate)-polyethylene glycol ester
 ligands" in Applied Organometallic Chemistry, 29, no. 1 (2015):20-25,
https://doi.org/10.1002/aoc.3238 . .